Optimal antiretroviral therapy for aging

Sexual Health

Volumn 8, Issue 4, 2011, Pages 534-540

  Cordery, Damien V ^a   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

highly active antiretroviral therapy; HIV.

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

AGING; ARTICLE; BONE DENSITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG METABOLISM; DYSLIPIDEMIA; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; METABOLIC SYNDROME X; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE PROGRESSION; HEALTH SERVICES FOR THE AGED; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; NERVOUS SYSTEM DISEASES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 81055133528     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH11026     Document Type: Article

References (70)

1. Bhavan KP, Kampalath VN, Overton ET.The aging of the HIV epidemic.Curr HIV/AIDS Rep 2008; 5: 150-8.doi:10.1007/s11904- 008-0023-3
2. National Centre in HIV Epidemiology and Clinical Research (NCHECR).HIV, viral hepatitis and sexually transmissible infections in Australia, Annual Surveillance Report, 2010.Sydney: NCHECR; 2010.Available online at: http://www.nchecr.unsw.edu.au/NCHECRwebnsf/resources/SurvRep07/file/ ASR2010-rev1pdf [verified January 2011].
3. Centers for Disease Control (CDC).CDC HIV surveillance report, 2008.Atlanta: CDC; 2008.Available online at: http://www.cdc.gov/ hiv/surveillance/resources/reports/2008report/pdf/2008Surveillance Report.pdf [verified November 2010].
4. Gebo KA.HIV infection in older people.BMJ 2009; 338: b1460.doi:10.1136/ bmj.b1460
5. Mapping HIV outcomes: geographical and clinical forecasts of numbers of people living with HIV in Australia, 2010.Sydney: NCHECR; 2010.Available online at: http://napwa.org.au/papers/ 2010/napwa-and-nchecr-jointly-launch-report- mapping-hiv-outcomes [verified October 2010].
6. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez- Barradas M, et al.Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45: 1593-601.doi:10.1086/ 523577 (Pubitemid 351411845)
7. Carre N, Deveau C, Belanger F, Boufassa F, Persoz A, Jadand C, et al.Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients.SEROCO Study Group.AIDS 1994; 8: 797-802.doi:10.1097/00002030-199406000-00012 (Pubitemid 24163423)
8. + T-cell counts.J Acquir Immune Defic Syndr 1991; 4: 970-5.
9. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.Response to combination antiretroviral therapy: variation by age.AIDS 2008; 22: 1463-73.doi:10.1097/QAD.0b013e3282f88d02
10. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr.Older age and the response to and tolerability of antiretroviral therapy.Arch Intern Med 2007; 167: 684-91.doi:10.1001/archinte.167.7.684 (Pubitemid 46598461)
11. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, et al.Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.AIDS 2008; 22: 2461-9.doi:10.1097/ QAD.0b013e328314b5f1
12. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al.Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.AIDS 2004; 18(Suppl 1): 19-25.doi:10.1097/00002030- 200401001-00004
13. Appay V, Rowland-Jones SL.Premature ageing of the immune system: the cause of AIDS? Trends Immunol 2002; 23: 580-5.doi:10.1016/S1471-4906(02)02338-4 (Pubitemid 35449096)
14. Volberding PA, Deeks SG.Antiretroviral therapy and management of HIV infection.Lancet 2010; 376: 49-62.doi:10.1016/S0140-6736 (10)60676-9
15. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R.Premature aging of T cells is associated with faster HIV-1 disease progression.J Acquir Immune Defic Syndr 2009; 50: 137-47.doi:10.1097/QAI.0b013e3181926c28
16. The Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet 2008; 372: 293-9.doi:10.1016/S0140-6736(08)61113-7 (Pubitemid 352020438)
17. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al.Survival of persons with and without HIV infection in Denmark, 1995-2005.Ann Intern Med 2007; 146: 87-95. (Pubitemid 351640011)
18. Deeks SG, Phillips AN.HIV infection, antiretroviral treatment,ageing, and non-AIDS related morbidity.BMJ 2009; 338: a3172.doi:10.1136/bmj.a3172
19. + count and risk of non-AIDS diseases following initial treatment for HIV infection.AIDS 2008; 22: 841-8.doi:10.1097/ QAD.0b013e3282f7cb76 (Pubitemid 351563833)
20. Klotz U.Pharmacokinetics and drug metabolism in the elderly.Drug Metab Rev 2009; 41: 67-76.doi:10.1080/03602530902722679
21. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK.Age changes in body composition revealed by computed tomography.J Gerontol 1983; 38: 673-7 (Pubitemid 13023392)
22. Salles N.Basic mechanisms of the aging gastrointestinal tract.Dig Dis 2007; 25: 112-7.doi:10.1159/000099474 (Pubitemid 46663776)
23. Rhee MS, Greenblatt DJ.Pharmacologic consideration for the use of antiretroviral agents in the elderly.J Clin Pharmacol 2008; 48: 1212-25.doi:10.1177/0091270008322177
24. Shah SS, McGowan JP, Smith C, Blum S, Klein RS.Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City.Clin Infect Dis 2002; 35: 1238-43.doi:10.1086/ 343048 (Pubitemid 35305872)
25. Grunfeld C.Dyslipidemia and its treatment in HIV infection.Top HIV Med 2009; 18: 112-8.
26. Kearney F, Moore AR, Donegan CF, Lambert J.The ageing of HIV: implications for geriatric medicine.Age Ageing 2010; 39: 536-41.doi:10.1093/ ageing/afq083
27. Samaras K.Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.J Antimicrob Chemother 2008; 61: 238-45.doi:10.1093/ jac/dkm475
28. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet 1999; 353: 2093-9.doi:10.1016/S0140-6736(98)08468-2 (Pubitemid 29278477)
29. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al.Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.Clin Infect Dis 2001; 32: 130-9.doi:10.1086/317541 (Pubitemid 32150958)
30. Brown TT, Qaqish RB.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS 2006; 20: 2165-74.doi:10.1097/QAD.0b013e32801022eb (Pubitemid 44684707)
31. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA, et al.Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.Diabetes 2002; 51: 3163-9.doi:10.2337/diabetes.51.11.3163 (Pubitemid 35246961)
32. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.AIDS 2002; 16: F1-8.doi:10.1097/00002030- 200203290-00002 (Pubitemid 34274457)
33. Noor MA, Flint OP, Maa JF, Parker RA.Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.AIDS 2006; 20: 1813-21.doi:10.1097/01.aids. 0000244200.11006.55 (Pubitemid 44358899)
34. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al.Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.AIDS 2007; 21: 1739-45.doi:10.1097/QAD. 0b013e32827038d0 (Pubitemid 47237561)
35. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al.HIV and metabolic syndrome: a comparison with the general population.J Acquir Immune Defic Syndr 2007; 45: 426-31.doi:10.1097/QAI.0b013e318074ef83 (Pubitemid 47057669)
36. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al.Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.AIDS 2007; 21: 2445-53.doi:10.1097/ QAD.0b013e3282efad32 (Pubitemid 350145176)
37. Carr A.HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.AIDS 2003; 17: S141-8.doi:10.1097/00002030- 200304001-00017 (Pubitemid 36667790)
38. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al.Combination antiretroviral therapy and the risk of myocardial infarction.N Engl J Med 2003; 349: 1993-2003.doi:10.1056/NEJMoa030218 (Pubitemid 37448922)
39. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al.Class of antiretroviral drugs and the risk of myocardial infarction.N Engl J Med 2007; 356: 1723-35.doi:10.1056/NEJMoa062744 (Pubitemid 46658704)
40. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.Lancet 2008; 371: 1417-26.doi:10.1016/S0140-6736(08)60423-7
41. Costagliola D, Lang S, Mary-Krause M, Boccara F.Abacavir and cardiovascular risk: reviewing the evidence.Curr HIV/AIDS Rep 2010; 7: 127-33.doi:10.1007/s11904-010-0047-3
42. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al.Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-74.doi:10.1086/381783 (Pubitemid 38373099)
43. Aberg JA.Lipid management in patients who have HIV and are receiving HIV therapy.Endocrinol Metab Clin North Am 2009; 38: 207-22.doi:10.1016/j.ecl.2008. 11.009
44. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al.Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.Arch Intern Med 2006; 166: 1632-41.doi:10.1001/archinte. 166.15.1632 (Pubitemid 44232373)
45. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, et al.The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.AIDS 2005; 19: 463-71.doi:10.1097/01.aids.0000162334.12815.5b (Pubitemid 40515849)
46. Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G.Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.PLoS ONE 2010; 5: e9183.doi:10.1371/journal.pone.0009183
47. Moodie EE, Pant Pai N, Klein MB.Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-monoinfected and HIV/hepatitis C co-infected cohorts.PLoS ONE 2009; 4: e4517.doi:10.1371/journal. pone.0004517
48. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE.Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.J Am Soc Nephrol 2005; 16: 2412-20.doi:10.1681/ASN.2005040340 (Pubitemid 41725059)
49. Perazella MA.Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.Kidney Int 2010; 78: 1060-3.doi:10.1038/ki.2010.344
50. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M.Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.Clin Infect Dis 2010; 51: 496-505.doi:10.1086/655681
51. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney Int 2010; 78: 1171-7.doi:10.1038/ki.2010.318
52. Carr A, Miller J, Eisman JA, Cooper DA.Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.AIDS 2001; 15: 703-9.doi:10.1097/ 00002030-200104130-00005 (Pubitemid 32423217)
53. Mallon PW.HIV and bone mineral density.Curr Opin Infect Dis 2010; 23: 1-8.doi:10.1097/QCO.0b013e328334fe9a
54. Papaioannou A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM, et al.Risk factors for low BMD in healthy men age 50 years or older: a systematic review.Osteoporos Int 2009; 20: 507-18.doi:10.1007/s00198-008-0720-1
55. Waugh EJ, Lam MA, Hawker GA, McGowan J, Papaioannou A, Cheung AM, et al.Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature.Osteoporos Int 2009; 20: 1-21.doi:10.1007/s00198-008- 0643-x
56. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS.Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection.AIDS 2007; 21: 617-23.doi:10.1097/QAD. 0b013e3280148c05
57. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE.HIV infection and bone mineral density in middle-aged women.Clin Infect Dis 2006; 42: 1014-20.doi:10.1086/ 501015
58. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, et al.Risk factors for decreased bone density and effects of HIV on bone in the elderly.Osteoporos Int 2008; 19: 913-8.doi:10.1007/s00198-007-0524-8
59. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA 2004; 292: 191-201.doi:10.1001/jama.292.2.191 (Pubitemid 38917996)
60. Dolan SE, Kanter JR, Grinspoon S.Longitudinal analysis of bone density in human immunodeficiency virus-infected women.J Clin Endocrinol Metab 2006; 91: 2938-45.doi:10.1210/jc.2006- 0127 (Pubitemid 44271739)
61. Bolland MJ, Grey AB, Gamble GD, Reid IR.Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis.J Clin Endocrinol Metab 2007; 92: 4522-8.doi:10.1210/jc.2007-1660 (Pubitemid 350223420)
62. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al.Continuous antiretroviral therapy decreases bone mineral density.AIDS 2009; 23: 1519-29.doi:10.1097/QAD.0b013e3283 2c1792
63. Hansen AB, Lohse N, Gerstoft J, Kronborg G, Laursen A, Pedersen C, et al.Cause-specific excess mortality in siblings of patients co-infected with HIV and hepatitis C virus.PLoS ONE 2007; 2: e738.doi:10.1371/journal.pone.0000738 (Pubitemid 351338874)
64. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al.Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Clin Infect Dis 2010; 51: 937-46.doi:10.1086/656412
65. White DA, Heaton RK, Monsch AU.Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals.The HNRC Group.HIV Neurobehavioral Research Center.J Int Neuropsychol Soc 1995; 1: 304-15.doi:10.1017/ S1355617700000308
66. Letendre SL, Ellis RJ, Ances BM, McCutchan JA.Neurologic complications of HIV disease and their treatment.Top HIV Med 2010; 18: 45-55.
67. Blanch J, Martinez E, Rousaud A, Blanco JL, Garcia-Viejo MA, Peri JM, et al.Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.J Acquir Immune Defic Syndr 2001; 27: 336-43. (Pubitemid 32729079)
68. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al.Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system.Arch Neurol 2008; 65: 65-70.doi:10.1001/archneurol.2007.31
69. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al.Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.AIDS 2009; 23: 1359-66.doi:10.1097/QAD. 0b013e32832c4152
70. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, et al.Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1- infected individuals commencing cART? A randomized, controlled study.Clin Infect Dis 2010; 50: 920-9.doi:10.1086/650743